A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients

Clinical Nephrology

Volumn 77, Issue 2, 2012, Pages 126-136

  Kamar, Nassim ^a   Rostaing, Lionel ^a   Cassuto, Elisabeth ^b   Villemain, Florence ^c   Moal, Marie Christine ^d   Ladrière, Marc ^e   Barrou, Benoît ^f   Ducloux, Didier ^g   Chaouche, Kamel ^h   Quéré, Stephane ^h   Di Giambattista, Fabienne ^h   Berthoux, François ⁱ  

^a CHU RANGUEIL   (France)

^b PASTEUR HOSPITAL   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e CHU NANCY BRABOIS   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g HÔPITAL SAINT JACQUES   (France)

^h NOVARTIS PHARMA K K   (Japan)

ⁱ HÔPITAL NORD   (France)

Author keywords

Ec MPS; Enteric coated; Mmf; Mycophenolic acid; Tacrolimus

Indexed keywords

CORTICOSTEROID; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; CREATININE; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BRONCHITIS; CONSTIPATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENTERIC COATED TABLET; FEMALE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GOUT; GRAFT RECIPIENT; HUMAN; HYGROMA; HYPERTENSION; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERTRIGO; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; PERIPHERAL EDEMA; PNEUMOCYSTIS PNEUMONIA; PRURITUS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREMOR; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; ADOLESCENT; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; TABLETS, ENTERIC-COATED; TACROLIMUS;

EID: 84859505163     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107227     Document Type: Article

References (26)

1. Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, Barr ML, Leichtman AB. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006; 6: 1111-1131.
2. Kaplan B, Meier-Kriesche HU, Minnick P, Bastien MC, Sechaud R, Yeh CM, Balez S, Picard F, Schmouder R. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant. 2005; 19: 551-558.
3. Grinyó JM, Ekberg H, Mamelok RD, Oppenheimer F, Sánchez-Plumed J, Gentil MA, Hernandez D, Kuypers DR, Brunet M. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant. 2009; 24: 2269-2276.
4. Park JM, Lake KD, Cibrik DM. Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. Ther Drug Monit. 2008; 30: 591-596.
5. Patel CG, Harmon M, Gohh RY, Akhlaghi F. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus. Ther Drug Monit. 2007; 29: 87-95.
6. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006; 28: 145-154.
7. Squifflet JP, Bäckman L, Claesson K, Dietl KH, Ekberg H, Forsythe JL, Kunzendorf U, Heemann U, Land W, Morales JM, Mühlbacher F, Talbot D, Taube D, Tyden G, van Hooff J, Schleibner S, Vanrenterghem Y; European Tacrolimus-MMF Renal Study Group. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation. 2001; 72: 63-69.
8. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant. 2008; 22: 1-15.
9. Ekberg H. Calcineurin inhibitor sparing in renal transplantation. Transplantation. 2008; 86: 761-767.
10. Moore J, Middleton L, Cockwell P, Adu D, Ball S, Little MA, Ready A, Wheatley K, Borrows R. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation. 2009; 87: 591-605.
11. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357: 2562-2575.
12. Ekberg H, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007; 7: 560-570.
13. Frimat L, Cassuto-Viguier E, Charpentier B, Noël C, Provôt F, Rostaing L, Glotz D, Sraer JD, Bourbigot B, Moulin B, Lang P, Ducloux D, Pouteil-Noble C, Girardot-Seguin S, Kessler M. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant. 2006; 6: 2725-2734.
14. Hueso M, Bover J, Serón D, Gil-Vernet S, Sabaté I, Fulladosa X, Ramos R, Coll O, Alsina J, Grinyó JM. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation. 1998; 66: 1727-1731.
15. Afzali B, Shah S, Chowdhury P, O'Sullivan H, Taylor J, Goldsmith D. Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation. 2005; 79: 304-309.
16. Kerecuk L, Taylor J, Clark G. Chronic allograft nephropathy and mycophenolate mofetil introduction in paediatric renal recipients. Pediatr Nephrol. 2005; 20: 1630-1635.
17. Pöge U, Gerhardt T, Palmedo H, Klehr H-U, Sauerbruch T, Woitas RP. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant. 2005; 5: 1306-1311.
18. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F; ZEUS Study Investigators. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011; 377: 837-847.
19. Holdaas H, Bentdal O, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant. 2008; 22: 366-371.
20. Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, Moulin B, Frouget T, Le Meur Y, Glotz D, Heng AE, Onno C, Buchler M, Girardot-Seguin S, Hurault de Ligny B. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant. 2009; 9: 1115-1123.
21. Weir M, Mulgaonkar S, Chan L, Shidban H, Waid TH, Preston D, Kalil RN, Pearson T. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int. 2011; 79: 897-907.
22. Guba M, Pratschke J, Hugo C, Krämer BK, Nohr-Westphal C, Brockmann J, Andrassy J, Reinke P, Pressmar K, Hakenberg O, Fischereder M, Pascher A, Illner WD, Banas B, Jauch KW; SMART-Study Group. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitorbased quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation. 2010; 90: 175-183.
23. Schena FP, Pascoe MD, Alberu J, Del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009; 87: 233-242.
24. Hazzan M, Labalette M, Copin MC, Glowacki F, Provôt F, Pruv FR, Noël C. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J Am Soc Nephrol. 2005; 16: 2509-2516.
25. Abramowicz D, Manas D, Lao M, Vanrenterghem Y, Del Castillo D, Wijngaard P, Fung S; Cyclosporine Withdrawal Study Group. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation. 2002; 74: 1725-1734.
26. Abramowicz D, Del Carmen Rial M, Vitko S, del Castillo D, Manas D, Lao M, Gafner N, Wijngaard P; Cyclosporine Withdrawal Study Group. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol. 2005; 16: 2234-2240.